Literature DB >> 17289836

Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.

Dorrah Deeb1, Hao Jiang, Xiaohua Gao, Shaza Al-Holou, Andrew L Danyluk, Scott A Dulchavsky, Subhash C Gautam.   

Abstract

Our previous studies have shown that dietary pigment curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L)-induced apoptosis by inhibiting nuclear factor (NF)-kappaB. In the present study, we demonstrate that activated (phosphorylated) Akt kinase plays a pivotal role in regulation of NF-kappaB and sensitization of LNCaP and PC3 prostate cancer cells to TRAIL by curcumin. Curcumin inhibited the expression of phospho-Akt (p-Akt), which was not due to activation of phosphatase and tensin homolog deleted on chromosome 10 phosphatase activity by curcumin. Because NF-kappaB is a downstream target of Akt, we investigated whether inhibition of NF-kappaB by curcumin is mediated through suppression of p-Akt. Data demonstrate that treatment of PC3 cells with SH-6 (JAm Chem Soc 125:1144-1145, 2003), a specific inhibitor of Akt, or transfection with small inhibitory RNA (siRNA)-Akt not only inhibited p-Akt but also abrogated the expression and transcriptional activity of NF-kappaB. Furthermore, overexpression of constitutively active Akt1 in cancer cells prevented the inhibition of NF-kappaB by curcumin. In addition, treatment with SH-6 or transfection with siRNA-Akt sensitized PC3 cells to TRAIL-induced cytotoxicity. On the other hand, SH-6 does not inhibit NF-kappaB or sensitize DU145 cancer cells to TRAIL because these cells do not express p-Akt. Because expression of antiapoptotic Bcl-2, Bcl-xL, and X-chromosome-linked inhibitor of apoptosis protein (XIAP) is regulated by NF-kappaB, both curcumin and SH-6 decreased the levels of these proteins in PC3 cells through inhibition of NF-kappaB. Furthermore, gene silencing of Bcl-2 with siRNA-Bcl-2 sensitized PC3 cells to TRAIL. Collectively, these data define a pathway whereby curcumin sensitizes prostate cancer cells to TRAIL by inhibiting Akt-regulated NF-kappaB and NF-kappaB-dependent antiapoptotic Bcl-2, Bcl-xL, and XIAP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17289836     DOI: 10.1124/jpet.106.117721

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

Review 1.  NutriTRAILomics in prostate cancer: time to have two strings to one's bow.

Authors:  Ammad Ahmad Farooqi; Aamir Rana; Asma M Riaz; Ammara Khan; Muhammad Ali; Sara Javed; Shahzeray Mukhtar; Sehrish Minhaj; Javeria Rafique Rao; Javairia Rajpoot; Rafia Amber; Fiza Asif Javed; Reema Khanum; Shahzad Bhatti
Journal:  Mol Biol Rep       Date:  2011-12-06       Impact factor: 2.316

Review 2.  Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?

Authors:  Guillaume Jacquemin; Sarah Shirley; Olivier Micheau
Journal:  Cell Mol Life Sci       Date:  2010-05-29       Impact factor: 9.261

3.  Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism.

Authors:  Siwang Yu; Guoxiang Shen; Tin Oo Khor; Jung-Hwan Kim; Ah-Ng Tony Kong
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

4.  Efficacy of turmeric (curcumin) in pain and postoperative fatigue after laparoscopic cholecystectomy: a double-blind, randomized placebo-controlled study.

Authors:  Krishna Adit Agarwal; C D Tripathi; Brij B Agarwal; Satish Saluja
Journal:  Surg Endosc       Date:  2011-06-14       Impact factor: 4.584

5.  Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Authors:  Karuppaiyah Selvendiran; Liyue Tong; Anna Bratasz; M Lakshmi Kuppusamy; Shabnam Ahmed; Yazhini Ravi; Nancy J Trigg; Brian K Rivera; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

6.  Traditional Chinese medicines and their active ingredients sensitize cancer cells to TRAIL-induced apoptosis.

Authors:  Bingyu Sun; Yongqiang Liu; Danhua He; Jinke Li; Jiawei Wang; Wulin Wen; Ming Hong
Journal:  J Zhejiang Univ Sci B       Date:  2021-03-15       Impact factor: 3.066

Review 7.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.

Authors:  Bharat B Aggarwal; Kuzhuvelil B Harikumar
Journal:  Int J Biochem Cell Biol       Date:  2008-07-09       Impact factor: 5.085

8.  Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator.

Authors:  Yan Jiao; John Wilkinson; Xiumin Di; Wei Wang; Heather Hatcher; Nancy D Kock; Ralph D'Agostino; Mary Ann Knovich; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2008-09-24       Impact factor: 22.113

9.  Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.

Authors:  Dorrah Deeb; Xiaohua Gao; Hao Jiang; Scott A Dulchavsky; Subhash C Gautam
Journal:  Prostate       Date:  2009-06-01       Impact factor: 4.104

10.  Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease.

Authors:  Madhavi Latha Yadav Bangaru; Jeffrey Woodliff; Hershel Raff; Sanjay Kansra
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.